Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder
Autore:
Fava, M; Rosenbaum, JF; Kolsky, AR; Alpert, JE; Nierenberg, AA; Spillmann, M; Moore, C; Renshaw, P; Bottiglieri, T; Moroz, G; Magni, G;
Indirizzi:
Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 Program, Boston, MA 02114 USA McLean Hosp, Imaging Ctr, Belmont, MA 02178 USA McLean Hosp Belmont MA USA 02178 Hosp, Imaging Ctr, Belmont, MA 02178 USA Baylor Univ, Med Ctr, Inst Metab Dis, Dallas, TX USA Baylor Univ Dallas TX USA Univ, Med Ctr, Inst Metab Dis, Dallas, TX USA Hoffmann La Roche Pharmaceut, Nutley, NJ USA Hoffmann La Roche PharmaceutNutley NJ USA he Pharmaceut, Nutley, NJ USA Hoffmann La Roche Pharmaceut, Basel, Switzerland Hoffmann La Roche Pharmaceut Basel Switzerland ceut, Basel, Switzerland
Titolo Testata:
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 4, volume: 19, anno: 1999,
pagine: 329 - 335
SICI:
0271-0749(199908)19:4<329:OSOTCI>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
PARKINSONS-DISEASE; COMT INHIBITOR; LEVODOPA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Fava, M Massachusetts Gen Hosp, Depress Clin & Res Program, ACC 812,15 Parkman St,Boston, MA 02114 USA Massachusetts Gen Hosp ACC 812,15 Parkman St Boston MA USA 02114 A
Citazione:
M. Fava et al., "Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder", J CL PSYCH, 19(4), 1999, pp. 329-335

Abstract

Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor that has shown efficacy in the treatment of Parkinson's disease. The authors undertook the first study on the efficacy of this COMT inhibitor in the treatment of major depressive disorder (MDD). The authors also wanted to assess the effects of tolcapone on the choline and myoinositol resonances in the left caudate and dorsolateral frontal lobe through proton magnetic resonance spectroscopy and on whole blood levels of S-adenosyl-L-methionine (SAMe). The studyenrolled 21 adults (10 men and 11 women; mean age, 42.6 +/- 9.6 years) with MDD, which was diagnosed using the Structured Clinical Interview for DSM-IV, and an initial score of greater than or equal to 16 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17). Patients were then treated openly for 8 weeks with tolcapone 400 mg twice daily. Treatment efficacy was assessed with the HAM-D-17, the Clinical Global Impressions Severity (CGI-S)scale, and the Beck Depression Inventory (BDI). Among all subjects (N = 21), there were significant (p < .0001) decreases at endpoint in HAM-D-17 scores (from 19.4 +/- 2.9 to 10.7 +/- 5.5), CGI-S scores (from 3.9 +/- 0.6 to 2.4 +/- 1.1), and BDI scores (from 21.6 +/- 8.1 to 12.3 +/- 8.6). Eight patients (38%) dropped out before completing the 8-week open study because of diarrhea, elevated liver function tests, increased anxiety, and noncompliance. No significant effects were noted on choline and myoinositol resonance or on SAMe levels in whole blood before and after 2 weeks of tolcapone treatment. The preliminary results suggest that tolcapone may be a promising agent in the treatment of MDD. Furthermore, double-blind, placebo-controlled studies are necessary to confirm this impression.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/10/20 alle ore 08:44:46